China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National Clinical Research Center for Infectious Diseases (NCRCID) to develop advanced tuberculosis diagnosis products. The collaboration aims to enhance diagnostic capabilities for tuberculosis, a critical area of focus for both organizations. No financial details were disclosed in the partnership agreement.
About NCRCID and Its Focus on Tuberculosis
NCRCID, the sole national clinical research center in Shenzhen, is dedicated to the prevention and treatment of infectious diseases, with a particular emphasis on tuberculosis. This partnership aligns with NCRCID’s mission to advance research and development in infectious disease diagnostics.
YHLO Bio’s Expertise in In Vitro Diagnostics
Founded in 2008, YHLO Bio specializes in the research and development, manufacturing, marketing, and sales of in vitro diagnosis (IVD) products. The company has established a robust portfolio of IVD technology platforms, including chemiluminescence, fluorescence immunochromatography, enzyme-linked immunosorbent assay, immunoblotting, indirect immunofluorescence, and colloidal gold immunochromatography. With over 300 products, YHLO Bio covers a wide range of areas such as autoimmune diseases, infection immunity, and liver disease detection.-Fineline Info & Tech
